FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)

View source ↗

Summary

FDA approved a supplemental application for ENSTILAR, a calcipotriene and betamethasone dipropionate combination, from LEO Pharma Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Enstilar (calcipotriene; betamethasone dipropionate)

Snippet

SUPPL AP for ENSTILAR (CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE)